UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-K

(Mark One)

x

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. FROM THE TRANSITION PERIOD FROM _____ TO _______.

 

For the fiscal year ended June 30, 2017

 

Commission file number 000-53239

 

 

Cavitation Technologies, Inc.
(Exact name of Registrant as Specified in its Charter)

 

Nevada		20-4907818
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

 

10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA  91311
(Address, including Zip Code, of Principal Executive Offices)

 

(818) 718-0905
(Registrant’s Telephone Number, Including Area Code)

 

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

 

NONE

 

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

 

Title of Each Class:		Name of Each Exchange on Which Registered:
Common Stock, $0.001 par value		Over the Counter (Bulletin Board)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES  ¨    NO  x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES  ¨    NO  x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES  x    NO  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  x    NO  ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K, or any amendment to this Form 10-K. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company x
		(Do not check if a smaller reporting company)	Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES  ¨    NO  x

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant by reference to the price at which the common equity was last sold, or of the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $6,365,938 as of December 31, 2016 based on the closing price of $0.04 per share and 159,148,456 non-affiliate shares outstanding.

 

The registrant had 196,797,906 shares of common stock outstanding on October 13, 2017.

 

DOCUMENTS INCORPORATED BY REFERENCE:

 

None

 

 

  

CAVITATION TECHNOLOGIES, INC.
FORM 10-K ANNUAL REPORT
FOR THE YEAR ENDED JUNE 30, 2017
TABLE OF CONTENTS

 

		Page
PART I
Item 1. Business		4
Item 1A. Risk Factors		7
Item 1B. Unresolved Staff Comments		7
Item 2. Properties		7
Item 3. Legal Proceedings		7
Item 4. Mine Safety Disclosures		7
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities		8
Item 6. Selected Financial Data		8
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations		8
Item 7A. Quantitative and Qualitative Disclosures About Market Risk		13
Item 8. Financial Statements and Supplementary Data		14
Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure		29
Item 9A. Controls and Procedures		29
Item 9B. Other Information		30
PART III
Item 10. Directors, Executive Officers and Corporate Governance		31
Item 11. Executive Compensation		32
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters		34
Item 13. Certain Relationships and Related Transactions, and Director Independence		35
Item 14. Principal Accounting Fees and Services		35
PART IV
Item 15. Exhibits, Financial Statement Schedules		36
Item 16. Form 10-K Summary		37
Signatures		38

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This annual report on Form 10-K and the exhibits attached hereto contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements concern our anticipated results and developments in our operations in future periods, planned exploration and development of our properties, plans related to our business and matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We use words like “expects,” “believes,” “intends,” “anticipates,” “plans,” “targets,” “projects” or “estimates” in this annual report. When used, these words and other, similar words and phrases or statements that an event, action or result “will,” “may,” “could,” or “should” result, occur, be taken or be achieved, identify “forward-looking” statements. Such forward-looking statements are subject to certain risks and uncertainties, both known and unknown, and assumptions.

 

Management has included projections and estimates in this annual report, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the Securities and Exchange Commission or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required by law. We qualify all of the forward-looking statements contained in this annual report by the foregoing cautionary statements.

 

 

PART I

 

ITEM 1.  BUSINESS

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. We are a process and product development firm that has developed, patented, and commercialized environmentally friendly technology based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, wines and spirits enhancement, algae oil extraction, water-oil emulsions and crude oil yield improvement.  Our systems are designed to process industrial liquids at a reduced processing time, lower operating cost, improved yield while operating in environmentally friendly manner. We have developed, patented, and commercialized our proprietary technology that can be used in multiple liquid processing applications. Our patented Nano Reactor® is the critical component of our CTi Nano Neutralization® System which has been shown to reduce operating costs and increase yields in refining vegetable oils.

 

Vegetable Oil Refining

 

Our first commercial application for our technology has been the CTi Nano Neutralization® System which has been utilized to improve edible vegetable oil refining process. Our environmentally friendly process has been shown to reduce refining costs, increase oil yield, and limit the amount of chemical additives used in chemical refining of vegetables oils. This patented process (US Patent # 7,762,715 and # 8,042,989) is designed to be incorporated into new and existing soybean, rapeseed, and canola oil chemical refineries.

 

Our first pilot test of our CTi NANO Neutralization System was conducted in 2010 at Carolina Soya, a 200-metric ton/day crude soy oil refining plant in Estill, South Carolina. Our second system, which became operational in fiscal 2011, has been continuously utilized since 2011 at the plant that processes approximately 450 metric tons per day of soy oil. Further, we have successfully shipped over 30 systems both domestically and abroad. We also continuously focus on developing additional Nano Reactor® applications and managing the intellectual property issues associated with new processes and applications.

 

The global demand for vegetable oils has grown consistently at a rate of about 5.5% p.a. from 84.5 million metric tons in 1999 to over 175 million metric tons in 2015-2016 (https://www.statista.com/statistics/263937/vegetable-oils-global-consumption/). It is also a highly competitive commodity market in which the lowest-cost producer has the advantage.

 

Desmet Ballestra Agreement

 

On May 14, 2012 we signed a global R and D, Marketing and Technology License Agreement with Desmet Ballestra Group s.a. (Desmet), a Belgian company that is actively marketing the NANO Neutralization System, the key component of which is our Nano Reactor® to soybean and other vegetable oil refiners. The Agreement provided Desmet (licensee) a limited, exclusive license and right to develop, design and supply our NANO Neutralization System which incorporates Nano Reactor® devices on a global basis tools and fats and oleo chemical applications Desmet provided, under certain conditions, limited monthly advance payments of $125,000 against future sales to us through May 2015. This Agreement was terminated in May 2015.

 

On January 22, 2016, we signed a similar three-year agreement with Desmet effective August 1, 2015. As part of the agreement, Desmet is to provide, under certain conditions, limited monthly advance payments of $50,000 against future sales to us. The agreement expires in August 2018 or may be terminated by Desmet every August 1 should Desmet and its affiliates fail to convert a minimum of six NANO Neutralization Systems to sold status during the period of June 1 to May 31. The agreement may also be terminated in case we were to lose our rights under the patents and patent applications being used in our CTi NANO Neutralization System.

 

Desmet, together with its affiliates, is a global engineering and equipment supply firm engaged in the development, design and supply of process equipment for oils and fats processing facilities including vegetable oil refining, biofuel, oleo chemical, seed crushing, surfactant and detergent markets. Desmet supplies these markets with services based on the latest globally sourced technologies. Desmet has relationships with major refiners globally A significant portion of global vegetable oil refineries include major refiners such as Archer Daniels Midland Company, Cargill, Inc. and Bunge Limited. Desmet has more than 40 sales representatives selling in North America, South America, Europe, and Asia. Since its founding in 1946, Desmet reports that it has built a global network that includes 1,300 employees, 17 global and 8 representative offices, and more than 5,700 lines in a variety of applications. Desmet operates a separate division for each of the above markets and the Desmet Oils & Fats division has supplied small and large plants to approximately 1,700 oil millers in 150 countries, covering over 6,000 process sections. We have developed a relationship with the North American arm of Desmet which operates in each of these markets and provides us with other potential opportunities such as palm oil refining.

 

 

We and Desmet have worked together to determine the appropriate sales approach and installation process. Our CTi Nano Neutralization System is designed to be used as an add-on process to an existing neutralization system within soybean and other vegetable oil refineries. Desmet is now focused on marketing our CTi’s Nano Neutralization® System to vegetable oil refiners to help them increase profits through cost savings and improved oil yields. Desmet purchases our CTi Nano Neutralization Reactor Systems from us and installs them at the refinery as part of an integrated neutralization system. Based on successful commercial implementations, Desmet guarantees minimum economic benefits to a facility that installs our CTi Nano Neutralization® Systems. We are therefore substantially dependent on Desmet to identify prospects, complete sales contracts, install the system and manage relationships with end-users.

 

GEA Westfalia Agreement

 

In August 2012, we entered into a Technology and Licensing Agreement with the GEA Group AG - Westfalia Separator Group (“GEA”) pursuant to which the companies agreed to jointly develop and patent new applications of our core technologies. As part of the Agreement, GEA Westfalia will assemble a complete commercial test system comprising Nano Reactors^®. This Agreement was terminated in January 2017.

 

In January 2017 we have entered into a new global technology license, R&D and marketing agreement with respect to our patented Nano Reactor™ technology, processes and applications. Under the new agreement, GEA has been granted a worldwide exclusive license to integrate our patented technology into water treatment application, milk and juice pasteurization, and certain food related processes. The license agreement between us and GEA has a three-year term and provides for the payment of $300,000 per year in advanced license fees to us. As of June 30, 2017, the Company has not received any advances from GEA or recorded any revenues pursuant to this agreement.

 

GEA Westfalia Separator manufactures filtration and equipment such as separators, clarifiers, decanters and membrane filtration systems. This equipment is used for the purification of suspensions, the separation of fluid mixtures with simultaneous removal of solids, extraction and concentration or removal of liquids from solids. The technological dominance of the company is based on over one hundred fifteen years of innovation, first-class engineering solutions and comprehensive processing capabilities. The company was founded in 1893 in Oelde, Germany, and since 1994 has been a part of the GEA Group AG and is a business unit within the GEA Mechanical Equipment segment. In 1950, Westfalia Separator established US and Canadian corporations to serve as sales and marketing arms to compete in the burgeoning North American market for centrifuges. GEA is one of the largest suppliers for the food processing industry and a wide range of process industries that generated consolidated revenues of approximately EUR 4.6 billion in 2015. As an international technology group, GEA focuses on process technology and components for sophisticated production processes in various end-user markets. The Group generates more than 70 percent of its revenue in the food sector that enjoys long-term sustainable growth. As of December 31, 2016, the Company employed about 17,000 people worldwide. GEA is a market and technology leader in its business areas. GEA is listed on the German MDAX (G1A, WKN 660 200). In addition, GEA’s share is a constituent of the MSCI Global Sustainability Indexes.

 

Customers Dependence

 

We continue to sell our CTi Nano Reactor® and Nano Reactor® Systems and technology only to two licensees, Desmet and GEA, and they are responsible for installing and servicing the systems. All of our revenue for the fiscal year ended June 30, 2017 and 2016 was derived from sales of products to Desmet.

 

Sources and availability of raw materials and the names of principal suppliers

 

We have historically sourced reactor components from various domestic and international suppliers. We do not have any long-term contracts, agreements, or commitments with any supplier. We believe it would take approximately 30 days to find a new supplier, if necessary.

 

Competition

 

Our competitors who sell equipment and engineering services for the vegetable oil refining business are a myriad of companies both large and small that provide equipment and technology to oil refiners. These include known companies that have longer operating histories, more experience, and stronger financial capabilities. Competitors include Alfa Laval, and Crown Iron Works as well as many firms that provide advice and services to small and regional firms. In addition, Arisdyne Systems, a designer of cavitation devices, is marketing a system using similar technology. The vegetable oil refining business is a highly competitive commodity market in which where the lowest-cost producer has the advantage. We intend to compete by offering solutions that help our clients remain or become a low-cost producer. Because the industry in which we compete has had limited new technology introduced in the last 50 years, we believe our CTi Nano Neutralization® Systems provide a unique opportunity for refiners to increase margins. We seek to differentiate ourselves by offering solutions based on our proprietary and patented designs, processes, and applications to help our clients described in our issued and patent pending applications. We compete by offering solutions that we believe can reduce operating expenses and increase oil yield vs currently applied technologies

 

 

Patents

 

Our Cavitation Generator patent was issued during fiscal 2011. In addition, we have a patent for our Multi-Stage Cavitation Device that was issued on October 25, 2011. In the fiscal 2014 we received approvals for another apparatus patent and 2 additional process patents in the US. During fiscal years 2015 and 2016, we also received approvals in the US for another 5 patents for various processes. In fiscal year 2017, we received approvals in the US for 3 process patents and approval for a 4^th process patent in fiscal year 2018.

 

In international applications, we received 1 patent approval for a process patent in Singapore in fiscal year 2016. In fiscal year 2017, we received patent approvals for process patents in Mexico and Canada.

 

We also have 3 US and 7 international patent applications pending that apply to the design of our reactor and the processes involving use of the same. We filed a number of process patent applications incorporating these patented devices for processing fluids in vegetable oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement. We received comments from the United States Patent and Trademark Office with regards to our process for increasing bioalcohol yield from biomass and have responded. We also received comments in multiples of our international applications and are responding to those as well. There is no assurance that our patents pending will be ultimately issued.

 

We believe our technology can be applied to other liquid processing industries where there is a need to solve environmental problems, reduce operating costs, and/or improve quality and yield. Our issued patents, allowed patents, and pending applications support potential uses of the Company’s proprietary technology in markets that include, but are not limited to, vegetable oils refining, renewable fuel production, alcoholic beverage enhancement, water purification, and algae oil extraction. In addition, we believe our proprietary technology may also be applied to fuel mixing and crude oil refining. During fiscal 2011, we received the “CE Marking” certification which allows us to market our systems in the European Union. Our success will depend in part on our ability to obtain patents, maintain trade secrets, and operate without infringing on the proprietary rights of others both in the United States and other countries. There can be no assurances that patents issued to us will not be challenged, invalidated, or circumvented, or that the rights granted hereunder will provide proprietary protection or competitive advantage to us. We plan to continue to invest in R&D and file for new and improved patents.

 

 Royalty Agreements

 

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President as well as our former Chief Executive Officer (CEO) who currently serves as our Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/current Technology Senior Manager have been assigned to the subsidiary.  In exchange, that subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by us on May 13, 2010 from our subsidiary. Our former CEO/current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2017.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with its former Director of Chemical and Analytical Department (the “Inventor”) to pay, in the first year, an amount equal to 5% of actual gross revenue received by us on any patent for which the Inventor was a legally named inventor, and, in each subsequent year, 3% of actual gross revenue received by us on any such patent. Since entering into that employment agreement, and during the term of this employment agreement, we have not received any revenue on any patents for which the Inventor was a legally named inventor.

 

Governmental Approval and Regulations and Environmental Compliance

 

Due to the nature of our products, we have incurred no costs with respect to environmental compliance with federal, state, and local laws. To our knowledge, our products do not require governmental approval, and we do not foresee that governmental regulations will have a material impact on our business.

 

Employees

 

On June 30, 2017 we had four full-time employees and had engaged several consultants and independent contractors over the past year. Members of our staff and technical team are comprised of experienced professionals who are chemists, civil, chemical, and mechanical engineers with expertise in hydrodynamic cavitation, nano technology and water treatment. These individuals hold degrees in Civil, Chemical, and Mechanical Engineering.

 

 

Research and Development Expenditures

 

During the fiscal years ended June 30, 2017 and 2016, we spent $27,105 and $29,371 on research and development activities.

 

ITEM 1A.  RISK FACTORS

 

Not applicable for smaller reporting companies.

 

ITEM 1B.  UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.  PROPERTIES

 

Our corporate headquarter is located in Chatsworth, California, with an area of approximately 5,000 square foot facility, which includes office space and an area to conduct research and development.  Our lease agreement for this space will end on February 1, 2018.  Our monthly rent payments approximate $5,000. We do not anticipate any material difficulties with the renewal of our rental agreement when it expires or in securing replacement facilities on commercially reasonable terms.

 

ITEM 3.  LEGAL PROCEEDINGS

 

We are involved in certain legal proceedings that arise from time to time in the ordinary course of our business. As of June 30, 2017, we were a party to legal proceedings related to claims for payment of unpaid wages that are currently accrued for in our financial statements and are described in more detail below. Except for income tax contingencies, we record accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. Material legal proceedings that are currently pending are as follows:

 

On September 5, 2013, a former employee who was also a former Director (Plaintiff) filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties and interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of us and dismissed the case. As a result of this ruling, our obligation to the former employee and former Director only amounted to approximately $131,000 which was accrued in prior periods and included as part of Accrued Payroll and payroll taxes due to officers in the accompanying balance sheet.

 

In February 2016, the same former employee and who is also a former Director has now appealed this ruling to the Los Angeles County Superior Court.  While we believe our case to be strong, no assurance can be given that we will prevail on appeal. In addition to defending ourselves, we also filed a cross-complaint against this former employee and Director for breach of contract and breach of fiduciary duty as a Director.

 

In October 2017, the Company settled the lawsuit with the Plaintiff for $30,000. Upon payment of the settlement amount, the Complaint and Cross-complaint between the Company and the Plaintiff will be dismissed with prejudice.  As a result, the Company will record a gain of $101,000 in October 2017 to extinguish the remaining accrual upon payment of the settled amount of $30,000.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

PART II

 

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Common Stock

 

Our Common Stock is traded on the OTCQB Market under the symbol CVAT. The following table sets forth the high and low price per share based on the closing price of our Common Stock for the periods indicated.

 

				HIGH				LOW
Fiscal 2016		First Quarter		$	0.06			$	0.03
		Second Quarter			0.03				0.02
		Third Quarter			0.04				0.02
		Fourth Quarter			0.04				0.03

 

				HIGH				LOW
Fiscal 2017		First Quarter		$	0.03			$	0.02
		Second Quarter			0.04				0.02
		Third Quarter			0.05				0.03
		Fourth Quarter			0.04				0.03
Fiscal 2018		First Quarter			0.04				0.03

 

We became a public company through a share exchange that was effected in October 2008. The first day of public trading of our stock was November 11, 2008. Since our fiscal year end was changed to June 30, public trading of our stock began in the second quarter of fiscal 2009. As of October 13, 2017, there were approximately 1,100 holders of record of our Common Stock. This does not reflect the number of persons or entities who hold stock in nominee or “street” name through various brokerage firms.

 

Dividend Policy

 

We have neither declared nor paid any dividends on our Common Stock in the preceding two fiscal years. We currently intend to retain future earnings, if any, to fund ongoing operations and finance the growth and development of our business and, therefore, do not anticipate declaring or paying cash dividends on our Common Stock for the foreseeable future. Any future decision to declare or pay dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors as the Board of Directors deems relevant.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

None.

 

Recent Sales of Equity Securities and Use of Proceeds

 

We did not sell any equity securities during the year ended June 30, 2017 in transactions that were not registered under the Securities Act of 1933, as amended, other than as previously disclosed in our filings with the Securities and Exchange Commission.

  

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6.   SELECTED FINANCIAL DATA

 

Not applicable for smaller reporting companies.

 

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

 

 

Overview of Our Business

 

We are a Nevada corporation originally incorporated under the name Bio Energy, Inc. On January 29, 2007, we incorporated a wholly owned subsidiary, Hydrodynamic Technology, Inc. as a California corporation.

 

We have developed, patented, and commercialized proprietary technology that can be used for processing of industrial fluids. Our patented Nano Reactor® is the critical components of the CTi Nano Neutralization® System which has been shown to reduce operating costs and increase yields in processing oils and fats. CTi holds and applied for numerous patents covering technology and various processes in US and Internationally, covering vegetable and crude oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

 

During the year ended June 30, 2017, we recorded revenue of $1,063,054. Our net loss from operations in 2017 was $1,066,945 and net cash used in operating activities was $53,311.

 

Management’s Plan of Operation

 

At June 30, 2017 we are continuously engaged in manufacturing Nano Reactor® and Nano Neutralization System which are designed to help refine vegetable oils such as soybean, canola and rapeseed. Additionally, our near-term goal is to develop strategic and marketing tools to apply our technologies that can be commercially accepted in enhancement of wines and spirits, industrial water treatment and consumer related products.

 

We have a working capital deficiency of $1,297,730 and a stockholders’ deficit of $1,144,720 as of June 30, 2017. The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.

 

Management’s plan is to generate income from operations by licensing our technology globally through our licensees, Desmet Ballestra Group (Desmet) and GEA Westfalia Group (GEA). In January 2016, we signed a three-year global R and D, Marketing and Technology License Agreement with Desmet for the sale and licensing of our reactors. The agreement expires in August 2018 or may be terminated by Desmet every August 1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors System to sold status during the period of June 1 to May 31. The agreement may also be terminated in case we lose ownership of patents and patent applications being used in our CTi Nano Neutralization System. As part of the agreement, Desmet is also obligated to provide us with monthly advances of $50,000 against future sales. During the year ended June 30, 2017, advances received from Desmet amounted to $500,000. These funds service operational expenses on a monthly basis.

 

In January 2017, we signed a three-year global R&D, Marketing and Technology License Agreement with GEA Group, (GEA) covering certain processes and patented applications. This agreement provides the Company with $25,000 monthly advances against future sales. This agreement may be terminated by either party on each anniversary date. As of June 30, 2017, the Company has not yet received any advances from GEA or recorded any revenues under this agreement. Subsequent to June 30, 2017, we received advances totaling $100,000.

  

In addition to these advances, we anticipate that we may need additional funding, and we may attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet our needs, or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we may curtail its operations. Management estimates that cash on hand together with advances from Desmet and GEA will allow us to operate beyond fiscal 2018.

 

The accompanying consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. As a result of the aforementioned factors, our independent auditors, in their report on our audited consolidated financial statements as of and for the year ended June 30, 2017, expressed substantial doubt about our ability to continue as a going concern.

 

Critical Accounting Policies and Revenue Recognition

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses. The accounting policies and estimates described below are those we consider most critical in preparing its consolidated financial statements. The following is a review of the accounting policies and estimates that include significant judgments made by management using information available at the time the estimates are made. However, these estimates could change materially if different information or assumptions were used instead.

 

 

Note 3 to our consolidated financial statements includes a summary of significant accounting policies, estimates, and methods used in the preparation of our financial statements. Accounting estimates are an integral part of the preparation of financial statements and are based on judgments by management using its knowledge and experience about the past and current events and assumptions regarding future events, all of which we consider to be reasonable. These judgments and estimates reflect the effects of matters that are inherently uncertain and that affect the carrying value of our assets and liabilities, the disclosure of contingent liabilities and reported amounts of expenses during the reporting period.

 

Revenue Recognition

 

Revenue from the sale of our Nano Reactor® systems is being recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability was reasonably assured. 

 

We are also entitled to a profit share from our distributor from the sale of the reactors to their customers.  Pursuant to the May 2012 agreement with our distributor, the profit share was fixed and determinable at the time of shipment, and as such, recorded upon shipment and acceptance of the reactors by the distributor. Pursuant to the January 2016 agreement with the Company’s distributor, the profit share is not fixed at the time of delivery, and as such, revenue is recognized when the profit share is fixed and determinable, which is generally be upon delivery and installation of the NANO Neutralization System by the distributor to its customer.

 

Recoverability of Intangible and Long-Lived Assets

 

Management believes that the accounting estimate related to the recoverability of its intangible and long-lived assets is a “critical accounting estimate” because significant changes in the assumptions used to develop the estimates could materially affect key financial measures, including net income and non-current assets.

 

Testing intangible and long-lived assets for impairment involves a high degree of judgment due to the assumptions that underlie the undiscounted cash flows analysis. In accordance with ASC 350-30, we evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the net book value may not be recoverable. When such factors and circumstances exist, we compare the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value based on market value when available or discounted expected cash flows of those assets and is recorded in the period in which the determination is made. Management believes there is no impairment of its long-lived assets. There can be no assurance, however, that market conditions will not change or demand for our products under development will continue. Either of these could result in future impairment of long-lived assets.

 

Share-Based Compensation

 

We periodically issue stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. We account for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

 

 

Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options and warrants will be outstanding prior to exercise, the associated volatility, and the expected dividends. We estimate the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period the options are expected to be outstanding and has been determined based on historical exercise experience. Expected stock price volatility is based on the historical volatility of our stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. We believe that these assumptions are “critical accounting estimates” because significant changes in the assumptions used to develop the estimates could materially affect key financial measures including net income (loss).

 

Recent Accounting Pronouncements

 

See Note 3 of the financial statements for discussion of recent accounting pronouncements.

 

Results of Operations

 

Below is summary comparing fiscal 2017 and fiscal 2016.

 

		For the Years Ended
		June 30,
		2017				2016				$ Change				% Change
Revenue		$	1,063,054			$	1,798,217			$	(735,163	)			-41	%
Cost of revenue			69,441				121,505				(52,064	)			-43	%
Gross profit			993,613				1,676,712				(683,099	)			-41	%
General and administrative expenses			2,033,453				1,214,561				818,892				67	%
Research and development expenses			27,105				29,371				(2,266	)			-8	%
Total operating expenses			2,060,558				1,243,932				816,626				66	%
Net income (loss)		$	(1,066,945	)		$	432,780				(1,499,725	)			-347	%

 

Revenue

 

During the year ended June 30, 2017 revenue decreased by 41% to $1,063,054 and was derived from the sale of eight of our CTi Nano Neutralization Systems and twenty-two reactor lines (a total of 66 reactors) delivered to Desmet as part of the revised agreement entered into in January 2016. During the year ended June 30, 2016, revenue of $1,798,217 was derived largely from the sale of four of our CTi Nano Neutralization Systems and 16 additional reactor lines in order to close-out the May 2012 agreement that expired in August 2015.

 

Operating Expenses

 

Operating expenses for fiscal 2017 amounted to $2,060,558 versus $1,243,932 in fiscal 2016, an increase of $816,626 or 66%. The increase was mostly attributable to non-cash costs resulting from the issuance of 2.8 million shares of common stock and 11.6 million warrants to acquire shares of our common stock to officers, consultants and a director of with a fair value of $545,000. Non-cash expense items such as amortization and depreciation expense of $50,967, and write-off of inventory $28,049 among others, amounted to a small proportion of operating expenses, with major expense categories being salaries and payroll taxes of approximately $548,000, legal and professional fees of approximately $376,000, various insurance policies amounting to $115,000 and travel, insurance and marketing services fees. Research and development (R&D) expense decreased by $2,266 or 7.7% for the year ended June 30, 2017.

 

 

Operating expenses for fiscal 2016 amounted to $1,243,932. Non-cash expense items such as amortization and depreciation expense of $60,126, and write-off of inventory of $18,792 among others, amounted to a small proportion of operating expenses, with major expense categories being salaries and payroll taxes of approximately $505,000, legal and professional fees of approximately $174,000, various insurance policies amounting to $96,333 and travel, insurance and marketing services fees.

 

Our reported Net Loss in fiscal 2017 was $1,066,945 vs Net Income in fiscal 2016 of $432,780.

 

Liquidity and Capital Resources

 

During the fiscal year ended on June 30, 2017, cash used in operating activities was $53,311 and cash used in investing activities was $55,500 resulting from the purchase of equipment which was financed with cash reserves and proceeds from reactor sales from our partner, Desmet Ballestra, resulted in net decrease in cash of $108,811.

 

During the fiscal year ended June 30, 2016, cash used in operating activities was $759,604 and cash used in investing activities was $61,565 resulting from the purchase of equipment of $61,565 resulted in net decrease in cash of $821,169.

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.  During the year ended June 30, 2017, we recorded net loss of $1,066,945 and utilized $53,311 of cash in operations. As of June 30, 2017, we had a working capital deficiency of $1,297,730, and stockholders’ deficit of $1,144,720.   We have also been dependent on certain aspects of our funding from a technology agreement with a distributor. These factors, among others, raise substantial doubt about our ability to continue as a going concern.

 

The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of us to continue as a going concern. In addition, our independent registered public accounting firm, in its report on our June 30, 2017 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern. Management’s plan is to generate income from operations by continuing to license our technology globally through our strategic partner with the Desmet Ballestra Group (Desmet). Pursuant to a R&D, Marketing and Technology License agreement with Desmet that was signed in January 2016, Desmet has provided us monthly advances of $50,000 which started in January of 2016 and are expected to continue up to the expiration of the agreement in August 2018 but can be terminated on each August 1 under certain circumstances. These advances will be applied against future sales to Desmet. During the year ended June 30, 2017 advances received from Desmet amounted to $500,000.

 

In January 2017, we signed a three-year global R&D, Marketing and Technology License Agreement with GEA Group, (GEA) covering certain processes and patented applications. This agreement provides the company with $25,000 monthly advances against future sales. This agreement may be terminated by either party on each anniversary date. As of June 30, 2017, the Company has not yet received any advances from GEA or recorded any revenues under this agreement. Subsequent to June 30, 2017, we received advances totaling $100,000.

 

We will also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet our needs, that we will be able to achieve profitable operations or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we may curtail its operations.

  

Sources and Uses of Cash

 

During the fiscal year ended June 30, 2017, net cash used in operating activities amounted to $53,311, a decrease over fiscal 2016 of almost $706,293. During the year ended June 30, 2017 we received proceeds totaling $1,373,750 from Desmet Ballestra from sale of reactors which included $500,000 in advances for gross profit share. This cash was used largely to pay operating costs, legal and professional service providers, acquire new inventory, pay management salaries and to pay travel and insurance expenses.

 

During fiscal 2016, net cash used in operating activities amounted to $759,604 and we received gross proceeds of $500,000 in advances against future gross profit share from our partner, Desmet Ballestra.

 

Net cash used in investing activities for property and equipment during fiscal 2017 and fiscal 2016 amounted to $55,500 and $61,565 respectively.

 

We did not conduct any financing activities in the fiscal years ended June 30, 2017 and 2016.

 

 

Off-balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

ITEM 7A.  Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable for Smaller Reporting Companies.

 

 

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors
Cavitation Technologies, Inc.
Los Angeles, CA

 

We have audited the accompanying consolidated balance sheets of Cavitation Technologies, Inc. (the “Company”) as of June 30, 2017 and 2016 and the related consolidated statements of operations, stockholders’ deficit and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform our audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that we considered appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cavitation Technologies, Inc. as of June 30, 2017 and 2016, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company has experienced recurring net losses since inception and has a stockholders’ deficit as of June 30, 2017. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Weinberg & Company, P.A.

Weinberg & Company, P.A.
Los Angeles, California
November 3, 2017

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS

 

		June 30,				June 30,
		2017				2016
ASSETS
Current assets:
Cash and cash equivalents		$	548,585			$	657,396
Inventory, net			143,136				153,811
Total current assets			691,721				811,207
Property and equipment, net			140,606				122,641
Patents, net			2,904				16,336
Other assets			9,500				9,500
Total assets		$	844,731			$	959,684
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses		$	245,452			$	171,029
Accrued payroll and payroll taxes due to officers			994,033				994,033
Related party payable			1,147				1,147
Advances from distributor, net			748,819				436,250
Total current liabilities			1,989,451				1,602,459
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2017 and 2016, respectively			-				-
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 196,797,906 and 193,997,906 shares issued and outstanding as of June 30, 2017 and 2016, respectively			196,798				193,998
Additional paid-in capital			22,625,088				22,062,888
Accumulated deficit			(23,966,606	)			(22,899,661	)
Total stockholders' deficit			(1,144,720	)			(642,775	)
Total liabilities and stockholders' deficit		$	844,731			$	959,684

 

See accompanying notes, which are an integral part of these consolidated financial statements

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

 

		For the Years Ended
		June 30,
		2017				2016
Revenue		$	1,063,054			$	1,798,217
Cost of revenue			69,441				121,505
Gross profit			993,613				1,676,712
General and administrative expenses			2,033,453				1,214,561
Research and development expenses			27,105				29,371
Total operating expenses			2,060,558				1,243,932
Net income (loss)		$	(1,066,945	)		$	432,780
Net income (loss) per share,
Basic and Diluted		$	(0.00	)		$	0.00
Weighted average shares outstanding,
Basic			195,053,401				193,997,906
Diluted			195,053,401				194,352,745

 

See accompanying notes, which are an integral part of these consolidated financial statements

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

YEARS ENDED JUNE 30, 2017 AND 2016

 

		Series A Preferred								Common Stock								Additional Paid-				Common Stock				Accumulated
		Shares				Amount				Shares				Amount				in Capital				Issuable				Deficit				Total
Balance at June 30, 2015			-			$	-				184,968,551			$	184,968			$	21,259,285			$	812,633			$	(23,332,441	)		$	(1,075,555	)
Issuance of common stock											9,029,355				9,030				803,603				(812,633	)							-
Net income																											432,780				432,780
Balance at June 30, 2016			-				-				193,997,906				193,998				22,062,888				-				(22,899,661	)			(642,775	)
Issuance of common stock for services											2,800,000				2,800				109,200				-								112,000
Fair value of warrants issued for services																			453,000												453,000
Net loss																											(1,066,945	)			(1,066,945	)
Balance at June 30, 2017			-			$	-				196,797,906			$	196,798			$	22,625,088			$	-			$	(23,966,606	)		$	(1,144,720	)

 

See accompanying notes, which are an integral part of these consolidated financial statements

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS 

 

		Years Ended June 30,
		2017				2016
Operating activities:
Net income (loss)		$	(1,066,945	)		$	432,780
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization			50,967				60,126
Fair value of common stock issued for services			112,000				-
Fair value of vested warrants			453,000				-
Allowance for inventory obsolescence			-				18,792
Changes in operating assets and liabilities:
Inventory			10,675				(37,004	)
Accounts payable and accrued expenses			74,423				(27,657	)
Accrued payroll and payroll taxes due to officers			-				(22,190	)
Advances from distributor			500,000				436,250
Reduction in advances due to realization of revenues from distributor			(187,431	)			(1,620,701	)
Net cash used in operating activities			(53,311	)			(759,604	)
Investing activities:
Purchase of property and equipment			(55,500	)			(61,565	)
Net cash used in investing activities			(55,500	)			(61,565	)
Net change in cash			(108,811	)			(821,169	)
Cash, beginning of period			657,396				1,478,565
Cash, end of period		$	548,585			$	657,396
Supplemental disclosures of cash flow information:
Cash paid for interest		$	-			$	-
Cash paid for income taxes		$	1,600			$	1,600

 

See accompanying notes, which are an integral part of these consolidated financial statements

 

 

CAVITATION TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2017 AND 2016

 

Note 1 - Organization

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi’s patented Nano Reactor® is the critical component of CTi Nano Neutralization® System which has commercially been shown to reduce operating costs and increase yields in refining vegetable oils. We have three US and one international patented systems, as well as eight US approved patents for various processes, and have filed another fifteen US and international patents to employ our proprietary technology in applications including vegetable and oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

 

In addition, we have commercialized our CTi Nano Neutralization® System in the refining process of certain vegetable oils which has proven to reduce costs and increase yields for our customers.

 

Note 2 - Basis of Presentation and Going Concern

 

Going Concern

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.  During the year ended June 30, 2017, the Company incurred a net loss of $1,066,945 and utilized $53,311 of cash in operations. As of June 30, 2017, the Company had a working capital deficiency of $1,297,730 and a stockholders’ deficit of $1,144,720. The Company has also been dependent on certain aspects of its funding from a technology and license agreement with a distributor that expires in August 2018. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern. Management’s plan is to generate income from operations by continuing to license its technology globally through our strategic partner with the Desmet Ballestra Group (Desmet). Pursuant to a R&D, Marketing and Technology License agreement with Desmet that was signed in January 2016, Desmet has provided the Company with monthly advances of $50,000 which started in January of 2016 and are expected to continue through expiration of the technology and license agreement in August 2018. These advances are expected to be applied against future sales to Desmet. During the year ended June 30, 2017 advances received from Desmet amounted to $500,000.

 

In January 2017, the Company signed a three-year global R&D, Marketing and Technology License Agreement with GEA Group, (GEA) covering certain processes and patented applications. This agreement provides the Company with $25,000 monthly advances against future sales, and may be terminated by either party on each anniversary date. As of June 30, 2017, the Company has not yet received any advances from GEA or recorded any revenues under this agreement. Subsequent to June 30, 2017, we received advances totaling $100,000.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Note 3 - Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.

 

Fair Value Measurement

 

FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

 

In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

  

Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

As of June 30, 2017, the carrying value of certain accounts such as inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserves for inventory obsolescence, valuing our stock options, stock warrants and common stock issued for services and realization of our deferred tax asset, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

Revenue from the sale of the Company’s Nano Reactor® Systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured.

 

The Company is also entitled to a profit share from its distributor from the sale of the reactors to their customers. Pursuant to the May 2012 agreement with our distributor, the profit share was fixed and determinable at the time of shipment, and as such, recorded upon shipment and acceptance of the reactors by the distributor. Pursuant to the January 2016 agreement with the Company’s distributor, the profit share is not fixed at the time of delivery, and as such, revenue is recognized when the profit share is fixed and determinable, which will generally be upon delivery and installation of the NANO Neutralization System by the distributor to its customer.

 

Cash

 

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents are carried at cost which approximates market value. 

 

The Company maintains its cash with one domestic financial institution. From time to time, cash balance in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000. As of June 30, 2017 and 2016, before adjustments for outstanding checks and deposits in transit, the Company had approximately $549,000 and $657,000, respectively, on deposit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

 

 

Inventory

 

Inventory, net of an allowance for excess quantities and obsolescence, is stated at the lower of cost or market. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s Nano Reactor® systems.

  

Property and Equipment

 

Property and equipment is presented at cost less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.

 

Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives.

 

Leasehold improvements		Shorter of life of asset or lease
Furniture		5-7 Years
Office equipment		5 Years
Lab equipment		4 Years
Skid systems		4 Years

 

Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. For the years ended June 30, 2017 and 2016, the Company did not recognize any impairment for its property and equipment.

 

Patents

 

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other Than Goodwill. The Company has five patents issued in fiscal 2013, 2012 and 2011. As of June 30, 2017, the Company has a total of 25 patents pending. The patents have duration of twenty years from filing date. The Company amortizes its patents over a four-year period which we believe is a reasonable estimate based upon its estimate of time until the next generation of reactors is developed or until other forms of competition appear.

 

During the year ended June 30, 2017, the Company recognized patent amortization expense of $13,432. As of June 30, 2017, total capitalized patent costs amounted to $129,363 and accumulated amortization of $126,459 or a net balance of $2,904.

 

During the year ended June 30, 2016, the Company recognized patent amortization expense of $20,830. As of June 30, 2016, total capitalized patent costs amounted to $129,363 and accumulated amortization of $113,027 or a net balance of $16,336.

 

At June 30, 2017, future estimated patent amortization costs are as follows:

 

Year Ended
June 30,		Amount
2018			2,904
Total		$	2,904

 

 

Impairment of Intangible and Long-Lived Assets

 

In accordance with ASC 350-30, General Intangibles Other than Goodwill, the Company evaluates amortizable intangibles and long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. Based on the Company annual impairment tests, management believes there is no impairment of its intangibles and long-lived assets as of June 30, 2017 and 2016. There can be no assurance, however, that market conditions will not change or demand for the Company’s products under development will continue. Either of these could result in future impairment of intangibles and long-lived assets.

 

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

 

The fair value of the Company’s common stock option and warrant grants is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options and warrants, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes.  The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.

 

The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

Advertising Costs

 

Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $30,996 and $45,241 for the years ended June 30, 2017 and 2016 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

 

Research and Development Costs

 

Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2017 and 2016 amounted to $27,105 and $29,371, respectively.

 

 

Warranty Policy

 

The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2017 and 2016.

  

Net Income (loss) Per Share

 

The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS.  Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period.  Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

The following table sets forth the computation of basic and diluted income per common share.

 

		June 30,
		2017				2016
Net income (loss)		$	(1,066,945	)		$	432,780
Weighted average common shares – basic			195,053,401				193,997,906
Dilutive effect of outstanding stock options			-				354,839
Weighted average shares – diluted			195,053,401				194,352,745
Net income (loss) per common share:
Basic and Diluted		$	(0.00	)		$	0.00

 

There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2017 and 2016, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been antidilutive.

 

		June 30, 2017				June 30, 2016
Options			11,685,852				12,241,153
Warrants			75,926,510				64,326,510

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The adoption of this pronouncement could affect the timing of the recognition of the Company’s revenues related to the gross profit share from the sale of reactors by our distributor to the end customer. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.

 

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures.

 

 

 

In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception ("ASU 2017-11"). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity's own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 can be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not expected to have any impact on the Company's financial statement presentation or disclosures.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements. 

 

Dependence on Desmet Ballestra

 

The Company’s revenue is entirely dependent on Desmet Ballestra who is its exclusive distribution agent with regard to the CTi Nano Neutralization® System for edible oils. During the year ended June 30, 2017 and 2016, 100% of the Company’s revenue was derived from Desmet (see Note 4).

 

Note 4 - Agreement with Desmet Ballestra

 

2012 Agreement

 

On May 14, 2012 the Company signed a three-year global Research and Development, Marketing and Technology License Agreement with the n.v. Desmet Ballestra Group s.a. (Desmet), a Belgian company that is actively marketing the NANO Neutralization System, the key component of which is the Company’s reactor to soybean and other vegetable oil refiners. The agreement provided Desmet (licensee) a limited, exclusive license and right to develop, design and supply Nano Reactor® systems which incorporate Nano Reactor® devices on a global basis but is limited to oils and fats and oleo chemical applications. The Company (licensor) remains owner of the current patents and patent applications but Desmet will be co-owner of any new process patent applications jointly developed. Desmet provided, under certain conditions, limited monthly advance payments of $125,000 against future sales to CTi through May 15, 2015. The agreement with Desmet expired in May 2015.

 

Pursuant to the 2012 Agreement, the Company was recognizing revenue from the sale of the reactors upon shipment and acceptance by Desmet as the Company had no further obligations to Desmet other than the reactor’s two-year standard warranty. In addition, the Company was also entitled to a non-refundable share in gross profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an integral component. Such revenues were recognized upon shipment of the reactors to Desmet as these amounts were fixed and the Company had no further obligation or commitment in the installation of the integrated neutralization system to Desmet’s customer, other than the reactors warranty.

 

During the year ended June 30, 2016 the Company recorded revenues from reactor sales of $420,001 and gross profit share of $1,200,700 or a total of $1,620,701 pursuant to the 2012 agreement.

 

As of June 30, 2016, the Company had no further obligations to Desmet under this agreement. There were no revenues recorded under this agreement in fiscal 2017.

 

2016 Agreement

 

On January 22, 2016, the Company signed a similar three-year agreement with Desmet effective August 1, 2015. In addition for the payment upon shipment of the nano reactors, Desmet agreed to provide monthly advance payments of $50,000 to be applied against gross profit share earned by the Company on installation of the nano reactors by Desmet to its customers. The agreement expires in August 2018 or may be terminated by Desmet every August 1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors systems to sold status during the period of June 1 to May 31. The agreement may also be terminated in case the Company were to lose its rights under the patents and patent applications being used in the Company’s CTi NANO Neutralization System.

 

 

Revenue from the sale of our Nano Reactor® systems is being recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability was reasonably assured.  We are also entitled to a profit share from our distributor from the sale of the reactors to their customers.  Pursuant to the January 2016 agreement with the Company’s distributor, the profit share is not fixed at the time of delivery, and as such, revenue is recognized when the profit share is fixed and determinable, which is generally be upon delivery and installation of the NANO Neutralization System by the distributor to its customer.

 

During the year ended June 30, 2016, the Company recorded revenues of $177,516 from reactor sales and received $500,000 of advance payments pursuant to the 2016 agreement. As of June 30, 2016, $63,750 of the recorded revenues was not yet collected, as such, for financial reporting purposes the Company deducted this amount from the advance payments received which resulted in a net balance of $436,250 in advances from Desmet.

 

During the year ended June 30, 2017, the Company recorded revenues of $895,000 from reactor sales and $168,054 from gross profit share for a total of $1,063,054 and received $500,000 of advance payments pursuant to the 2016 agreement. As of June 30, 2017, $85,000 of the recorded revenues was not yet collected, as such, for financial reporting purposes the Company deducted this amount from the advance payments received which resulted in a net balance of $748,819 in advances from Desmet.

 

Note 5 - Property and Equipment

 

Property and equipment consists of the following as of June 30, 2017 and June 30, 2016:

 

		June 30,				June 30,
		2017				2016
Leasehold improvement		$	2,475			$	2,475
Furniture			26,837				26,837
Office equipment			1,499				1,499
Equipment			68,380				68,380
Systems			408,155				352,655
			507,346				451,846
Less: accumulated depreciation and amortization			(366,740	)			(329,205	)
Property and equipment, net		$	140,606			$	122,641

 

Depreciation expense for the years ended June 30, 2017 and 2016 amounted to $37,535 and $39,296, respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

 

Note 6 - Accrued Payroll and Payroll Taxes to Officers and former officers

 

As of June 30, 2017 and 2016, the Company had accrued unpaid salaries to officers and former officers amounting to $994,033.

  

Note 7 - Stockholders’ Deficit

 

Common Stock

 

Year ended June 30, 2017

 

During the year ended June 30, 2017 the Company issued 2,800,000 shares of common stock valued at $112,000 to service providers and a director for services rendered. These shares were valued at fair value at the date of issuance.

 

Year ended June 30, 2016

 

On September 25, 2015, the Company issued 9,029,355 shares of common stock with a value of $812,633 pursuant to a settlement of notes payable in April 2014. These shares were reflected as Common Stock issuable in the accompanying Statement of Changes in Stockholders’ Deficit as of June 30, 2016. Such amounts were reclassified to additional paid in capital upon their issuance during the year ended June 30, 2016.

 

 

Preferred Stock

 

On March 17, 2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2017 and 2016, there are no shares of Series A or Series B Preferred Stock issued and outstanding.

 

Stock Options

 

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity from June 30, 2017 and 2016 is as follows:

 

										Weighted-
										Average
						Weighted-				Remaining
						Average				Contractual
						Exercise				Life
		Options				Price				(Years)
Outstanding June 30, 2015			12,810,957			$	0.44				5.35
- Granted			-				-				-
- Forfeited			-				-				-
- Exercised			-				-				-
- Expired			(214,965	)			-				-
Outstanding at June 30, 2016			12,595,992			$	0.44				4.96
- Granted			-				-				-
- Forfeited			-				-				-
- Exercised			-				-				-
- Expired			(910,140	)			-				-
Outstanding at June 30, 2017			11,685,852			$	0.37				2.41

 

As of June 30, 2017 and 2016, all outstanding options were fully vested and exercisable. The intrinsic value of the outstanding options as of June 30, 2017 was $110,000. The following table summarizes additional information concerning options outstanding and exercisable at June 30, 2017.

 

			Options Outstanding												Options Exercisable
							Weighted				Weighted								Weighted
							Average				Average								Average
Exercise			Number				Remaining				Exercise				Number				Remaining
Price			of Shares				Life (Years)				Price				of Shares				Life (Years)
$	0.03			11,000,000				5.36			$	0.03				11,000,000				5.36
$	0.33			174,022				0.89			$	0.33				174,022				0.89
$	0.67			511,830				0.97			$	0.67				511,830				0.97
				11,685,852												11,685,852

 

 

Warrants

 

A summary of the Company’s warrant activity and related information from as of June 30, 2017 and 2016 is as follows.

  

										Weighted-
										Average
						Weighted-				Remaining
						Average				Contractual
						Exercise				Life
		Warrants				Price				(Years)
Outstanding at June 30, 2015			68,259,843			$	0.07				5.77
Granted			-
Exercised			-
Expired			(3,933,333	)
Outstanding at June 30, 2016			64,326,510			$	0.07				5.09
Granted			11,600,000				0.03				7.5
Exercised			-
Expired			-
Outstanding at June 30, 2017			75,926,510			$	0.06				4.81

  

In January of 2017, the Company issued warrants to purchase 11,600,000 shares of common stock to Directors, Officers, employees and consultants. The warrants are exercisable at $0.03 per share, vesting immediately and expiring in 10 years from the grant date. Total fair value of these warrants at grant date was $453,000 using the Black-Scholes Option Pricing model with the following average assumptions: stock price of $0.04 per share, estimated life of 7.5 years; risk free interest rate of 2.15%; volatility of 173%, and dividend yield of 0%.

  

As of June 30, 2017 and 2016, all outstanding warrants were fully vested and exercisable. The intrinsic value of the outstanding warrants as of June 30, 2017 was $116,000. The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2017.

 

		Warrants Outstanding												Warrants Exercisable
						Weighted				Weighted								Weighted
						Average				Average								Average
Exercise		Number				Remaining				Exercise				Number				Exercise
Price		of Shares				Life (Years)				Price				of Shares				Price
0.03 - 0.07			55,599,851				6.75			$	0.05				55,599,851			$	0.05
0.12			20,326,659				3.25			$	0.12				20,326,659			$	0.12
			75,926,510												75,926,510

 

Note 8 - Income Taxes

 

Total income tax expense differed from the amounts computed by applying the U.S. Federal and state income tax rate before income tax expense as a result of the NOL carry forward. Therefore, the Company’s effective tax rate is 0.0%. The Company files income tax returns in the United States (“Federal”) and California (“State”) jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception.

 

At June 30, 2017, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of approximately $10 million. These carry forwards will begin to expire in the year ending June 30, 2018 through 2023, subject to IRS limitations, including change in ownership.

 

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors.

 

 

At June 30, 2017, based on the weight of available evidence, including cumulative losses in recent years and expectations of future taxable income, the Company determined that it was more likely than not that its deferred tax assets of approximately $4.4 million would not be realized. Accordingly, the Company has recorded a valuation allowance for 100% of its cumulative deferred tax assets. The components of our deferred tax assets are as follows.

 

		June 30,				June 30,
		2017				2016
Net Operating loss carryforwards		$	4,118,000			$	3,585,000
Stock compensation expense			957,000				725,000
Amortization of Patents			69,000				58,000
Reserve for Obsolete Inventory			68,000				68,000
Total net deferred tax assets			5,212,000				4,436,000
Less valuation discount			(5,212,000	)			(4,436,000	)
Net deferred tax assets		$	-			$	-

  

A reconciliation of the difference between the expense and income taxes as the statutory US federal income tax are as follows:

 

		June 30,				June 30,
		2017				2016
Federal statutory rate			(34	)%			34	%
State income taxes			(7	)%			7	%
Net operating loss/carryforward			41	%			(41	)%
Income tax provision			-				-

 

As a result of the implementation of certain provisions of ASC 740-10, the Company performed an analysis of its previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of June 30, 2017.

 

Future changes in the unrecognized tax benefit are not expected to have an impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change within the next twelve months. The Company will continue to classify income tax penalties and interest, if any, as part of interest and other expenses in its consolidated statements of operations. There is no interest or penalties accrued as of June 30, 2017.

 

The following summarizes the open tax years for each major jurisdiction:

 

Jurisdiction			Open Tax Years
Federal			2013 - 2017
California			2012 - 2017

 

The Company’s net operating loss carry forwards are subject to IRS examination until they are utilized and such tax years are closed. 

 

Note 9 - Commitments and Contingencies

 

Lease Agreement

 

The Company leases approximately 5,000 square feet of office and warehouse space under a non-cancellable operating lease agreement through February 1, 2018.  Monthly payments are approximately $5,000 per month. The Company has a security deposit of $9,500 associated with this lease. Future minimum lease payments under our non-cancelable operating lease through February 2018 are $35,000.

 

Total rent expense was $64,822 and $53,359 for the years ended June 30, 2017 and 2016 and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations,

 

 

Royalty Agreements

 

On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company.  In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2017.

 

On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of June 30, 2017, no patents have been granted in which this person is the legally named inventor.

 

Litigation

 

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies (commencing April 1, 2009), the Company records accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.

 

In August 2014, a former employee and former Director filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties and interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of the Company and dismissed the case. As a result of this ruling, the Company’s obligation to the former employee and former Director only amounted to approximately $131,000 which was already accrued in prior periods and included as part of Accrued Payroll and payroll taxes due to officers in the accompanying balance sheet.

 

In February 2016, the former employee and former Director appealed this ruling to the Los Angeles County Superior Court.  In addition to defending itself, the Company also has filed a cross-complaint against the former employee and former Director for breach of contract and breach of fiduciary duty as a Director. 

 

In October 2017, the Company settled the lawsuit with the Plaintiff for $30,000. Upon payment of the settlement amount, the Complaint and Cross-complaint between the Company and the Plaintiff will be dismissed with prejudice.  As a result, the Company will record a gain of $101,000 in October 2017 to extinguish the remaining accrual upon payment of the settled amount of $30,000.

 

Note 10 - Subsequent Events

 

In January 2017, we signed a three-year global R&D, Marketing and Technology License Agreement with GEA Group, (GEA) covering certain processes and patented applications. This agreement provides the Company with $25,000 monthly advances against future sales. This agreement may be terminated by either party on each anniversary date. In July 2017, the Company received advances totaling $100,000 pursuant to this agreement.

 

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A.  CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

In accordance with rule 13a-15(a), our management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

In accordance with Rule 13a-15(b) and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of June 30, 2017, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were not effective as of June 30, 2017.

  

 

Report of Management on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed under the supervision of our principal executive and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

 

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal controls and procedures, (as defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of the year ended June 30, 2017. Based on Management conducted as assessment of our internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our internal controls over financial reporting are ineffective. Our management discovered certain conditions that we deemed to be material weaknesses and significant deficiencies in our internal controls, as follows:

 

·

A lack of accounting and finance resources as well as effective oversight by those in charge of governance resulted in insufficient controls over timely financial statement preparation and review as well as the preparation and review around accounting for certain complex transactions.

 

·

The design of monitoring controls used to assess the design and operating effectiveness of our internal controls is inadequate. We also do not have an adequate internal process to report deficiencies in internal control to management on a timely basis.

 

·

A lack of control relating to the recognition of certain gross profit share earned upon delivery and acceptance to the end user by our distributor caused by improper communication between us and our distributor, which resulted in restatement of previously reported quarterly revenue.

 

We are in the continuous process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision and training of our staff, but additional effort is needed to fully remedy these deficiencies. We intend on hiring the necessary staff to address the weaknesses once additional capital is obtained which will allow full operations to commence. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

We have taken numerous steps to address the underlying causes of the internal control deficiencies, primarily through the development and implementation of policies, improved processes and documented procedures, the retention of third-party experts and contractors, and the hiring of additional accounting personnel with technical accounting and inventory accounting experience.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2017 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Attestation

 

Pursuant to Item 308(b) of Regulation S-K, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Wall Street Reform Act), this report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. The Wall Street Reform Act permanently exempts small public companies from the requirement to obtain an external audit on the effectiveness of internal financial reporting controls.

 

ITEM 9B.  Other Information

 

None.

 

 

PART III

 

ITEM 10. Directors, Executive Officers and Corporate Governance.

 

Person		Age				Position
Igor Gorodnitsky			57			President, PEO, Secretary & Director
Naum Voloshin			54			Principal Accounting Officer
James Fuller			77			Director
Gerald Bailey*			76			Director

 

·

Resigned in September of 2017

 

Audit committee standing members consisted of Igor Gorodnitsky and James Fuller as of June 30, 2017. We anticipate forming compensation, governance, and other committees as necessary.

 

Igor Gorodnitsky. Mr. Gorodnitsky has been our President and member of the Board of Directors since September 26, 2008, and he became the Company's Secretary and Principal Executive Officer in November of 2012. Mr. Gorodnitsky developed expertise in handling and processing hazardous waste material. As a Senior Haz-Mat Specialist, he coordinated and successfully completed more than 500 emergency response Haz-mat clean-ups over the past 20 years. He coordinated and supervised Haz Mat projects, emergency and routine spill clean-ups, and confined space entry tasks. He coordinated and scheduled manpower and purchased and scheduled equipment and materials for containment and treatment of spills. He successfully managed, coordinated and supervised projects including Hazscanning, sampling, lab-packing, manifesting, profiling, labeling, and other special procedures for a variety of commercial clients and municipalities. He is a chemist by training and holds numerous certifications and licenses including Hazwoper Training Program, Confined Space Entry and Gas Vapour HazCating, Certified Uniform Waste Manifest Training, Basic and Intermediate HazCating, On-Scene Incident Commander Emergency, Site Remediation Methods, Underground Storage Tank Removal, Health & Safety Supervisor Certification, Hazardous Certification, and Tosco Refinery Safety. Mr. Gorodnitsky was president of Express Environmental Corp. since its inception in 1980 until he sold his interest in January 2009. Based on his significant industry experience and management skills it was determined that Mr. Gorodnitsky should serve on the Company’s Board.

 

James Fuller. Mr. Fuller is an independent director, and has been Chairman of our Audit Committee and Independent Financial Expert since February 2010. He was formerly a Vice President of the New York Stock Exchange and director of the Securities Investor Protection Corporation. In addition to his over 30 years of experience in the securities markets, Mr. Fuller sat on the Board of Trustees of the University of California, Santa Cruz and previously served as Chairman of their Audit Committee and Independent Financial Expert. Jim is a partner at Baytree Capital Associates, LLC. He received his BS in Political Science from San Jose State University and his MBA from California State University - Fresno. Mr. Fuller also served as a Director of Propell Technologies Group, Inc (OTCQB: Propell), a public company engaged in oil and gas exploration from October 14, 2011 until February 17, 2015. Based on Mr. Fuller’s extensive experience in finance as well as his prior public company experience it was determined that Mr. Fuller should serve on the Company’s Board.

 

Naum Voloshin. Mr. Voloshin has over 20 years of experience in investment banking, business operations and marketing. Prior to joining CTi, Mr. Voloshin has worked for several developmental stage companies in US, Europe and Asia. The scope of his duties was to provide management, supervision, business experience and marketing skills.

 

Family Relationships

 

Roman Gordon, Global Technology Manager and Founder is a brother of Mr. Igor Gorodnitsky.

 

 Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors, persons who own more than 10% of our common stock, and immediate family members living in the same household to file an Initial Statement of Beneficial Ownership on Form 3 and changes in ownership on Form 4 with the Securities and Exchange Commission (the "SEC"). Such "insiders" are required by SEC rules to furnish us with copies of all Section 16(a) forms they file.

 

 

Based on a review of Forms 3, 4, and 5 and amendments thereto furnished to us during fiscal 2016 ended June 30, 2017, there were no delinquent forms filed during the year.

 

Director Independence

 

Although our common stock is not listed on a national securities exchange, for purposes of independence we use the definition of independence applied by the NASDAQ stock market. The Board has determined that Messrs. Zotos and Fuller are ”independent” in accordance with such definition. Messrs. Gorodnitsky and Gordon are not independent due to their current positions with the Company.

 

Code of Ethics

 

We have adopted a Code of Business Conduct and Ethics that applies to all officers, directors and employees. A copy may also be obtained free of charge by mailing a request in writing to: Cavitation Technologies, Inc., 10019 Canoga Ave., Chatsworth, CA 91311 USA. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver in a current report on Form 8-K.

 

ITEM 11. Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth a summary of cash and non-cash compensation awarded, earned or paid for services rendered to us during the years ended June 30, 2017 and 2016 by our “named executive officers,” consisting of (i) each individual serving as principal executive officer during the year ended June 30, 2017, and (ii) our Chief Financial Officer/Chief Operating Officer, our other executive officer.

 

																								Changes in
																								Pension
																								Value and
																				Non-Equity				Non-Qualified				All
												Stock				Warrant				Incentive Plan				Deferred				Other
		Year		Salary				Bonus				Awards (1)				Awards				Compensation				Compensation				Compensation				Totals
Igor Gorodnitsky *		2017		$	169,000	(1)		$	-				-			$	120,000			$	-			$	-			$	-			$	289,000
President, Principal Executive Officer		2016		$	169,000	(1)		$	-				-			$	-			$	-			$	-			$	-			$	169,000
Naum Voloshin		2017		$	156,000	(2)		$	-				-			$	120,000			$	-			$	-			$	-			$	276,000
Principal Accounting Officer		2016		$	97,000	(2)		$	-				-			$	-			$	-			$	-			$	-			$	97,000
Roman Gordon ***		2017		$	169,000	(3)		$	-				-			$	120,000			$	-			$	-			$	-			$	289,000
Chief Technology Officer (Resigned)		2016		$	169,000	(3)		$	-				-			$				$	-			$	-			$	-			$	169,000

 

·

Mr. Roman Gordon resigned as Chief Technology Officer

 

 

Outstanding Equity Awards at Fiscal Year-End

 

The table below reflects all outstanding equity awards made to each of the named executive officers that are outstanding as of June 30, 2017.  

  

						Option Awards
						Number				Number
						of securities				of securities
						Underlying				Underlying
		Option/warrant				Unexercised				Unexercised				Option/warrant				Option/warrant
		grant				Options/warrants				Options/warrants				Exercise				expiration
Name		date				# Exercisable				# Unexercisable				Price				date
Igor Gorodnitsky			12/18/2012				4,250,000				-			$	0.05				12/18/2022
President and			3/20/2013				5,000,000				-			$	0.04				3/20/2023
Principal Executive Officer			1/13/2017				3,000,000				-			$	0.03				1/13/2027
Roman Gordon			12/18/2012				4,250,000				-			$	0.05				12/18/2022
Senior Technology Manager			3/20/2013				5,000,000				-			$	0.04				3/20/2023
			1/13/2017				3,000,000				-			$	0.03				1/13/2027
Naum Voloshin			10/10/2013				3,000,000				-			$	0.04				10/10/2023
Principal Accounting Officer			1/13/2017				3,000,000				-			$	0.03				1/13/2027

 

The fair value of each option grant is estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is calculated based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield for a term equal to the expected life of the options at the time of grant.

 

Employment Agreements

 

Our executive officers work as at-will employees.

 

Code Section 162(m) Provisions

 

Section 162(m) of the U.S. Internal Revenue Code, or the Code, generally disallows a tax deduction to public companies for compensation in excess of $1 million paid to the Chief Executive Officer or any of the four most highly compensated officers. Performance-based compensation arrangements may qualify for an exemption from the deduction limit if they satisfy various requirements under Section 162(m). Although we consider the impact of this rule when developing and implementing our executive compensation programs, we believe it is important to preserve flexibility in designing compensation programs. Accordingly, we have not adopted a policy that all compensation must qualify as deductible under Section 162(m) of the Code. While our stock options are intended to qualify as “performance-based compensation” (as defined by the Code), amounts paid under our other compensation programs may not qualify as such. 

 

 

2016 Director Compensation

 

The following table sets forth information for the fiscal year ended June 30, 2017 regarding the compensation of our directors who at June 30, 2017 were not also named executive officers.

 

		Fees												Non-equity
		Earned												inventive				Non-qualified
		or paid				Stock				Option				plan				deferred				All other
		in cash				Awards				Awards				compensation				compensation				compensation				Total
Name		($)				($)				($)				($)				Earnings				($)				($)
James Fuller (1)		$	-			$	8,000			$	39,130			$	-			$	-			$	-			$	47,130
Gerald Bailey (resigned)		$	-			$	-			$	15,652			$	-			$	-			$	-			$	15,652

 

As of June 30, 2017 the following table sets forth the number of aggregate outstanding option awards held by each of our directors who were not also named executive officers:

 

Name		Aggregate Number of Option Awards
James Fuller			1,000,000
Gerald Bailey			400,000

 

ITEM 12.  Security Ownership of Certain Beneficial Owners and Management

 

The following table provides information regarding the beneficial ownership of our common stock as of October 18, 2017, (the “Evaluation Date”) by: (i) each of our current directors, (ii) each of our named executive officers, and (iii) all such directors and executive officers as a group. We know of no other person or group of affiliated persons who beneficially own more than five percent of our common stock. The table is based upon information supplied by our officers, directors and principal stockholders and a review of Schedules 13D and 13G, if any, filed with the SEC. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, we believe that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned.

 

Applicable percentages are based on 196,597,906 shares outstanding as of the Evaluation Date, adjusted as required by rules promulgated by the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of our common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable within 60 days of the Evaluation Date. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

 

						Amount and
						Nature of
				Title of		Beneficial				Percent of
Name of Beneficial Owner				Class		Ownership				Class (1)
Igor Gorodnitsky		(2)		Common Stock			21,573,475				10.5	%(3)
President , Principal Executive Officer, Director
James Fuller		(2)		Common Stock			1,037,500				0.5	%
Chairman of Audit Committee, Director
Roman Gordon		(2)		Common Stock			27,938,475				13.6	%(3)
Senior Technology Manager
Naum Voloshin		(2)		Common Stock			6,000,000				3.0	%
Principal Accounting Officer
Gerald Bailey *		(2)		Common Stock			400,000				0.2	%(5)
Director
West Point Partners LLC		(4)		Common Stock			15,220,000				7.45	%(4)
Directors and Officers				Common Stock			56,949,450				25.1	%
(as a group, five individuals)

 

*less than 1%

 

(1)	Unless otherwise set forth below, the mailing address of Executive Officers, Directors and 5% or greater holders is c/o the Company,

Igor Gorodnitsky

James Fuller

Jon Gruber >5% 

 

  

ITEM 13. Certain Relationships and Related Transactions

 

Certain Related Party Transactions

 

Since the beginning of our last fiscal year , there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years and in which any of our directors, executive officers, holders of more than five percent of any class of our voting securities or any member of the immediate family of the foregoing persons had or will have a direct or indirect material interest.

 

Director Independence

 

As our common stock is currently traded on the OTC Bulletin Board, we are not subject to the rules of any national securities exchange which require that a majority of a listed company's directors and specified committees of the board of directors meet independence standards prescribed by such rules. For the purpose of preparing the disclosures in this Report on Form 10-K regarding director independence, we have used the definition of "independent director" set forth in the Marketplace Rules of The NASDAQ, which defines an "independent director" generally as a person other than an executive officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Consistent with these standards, we believe that James Fuller is an Independent Financial Expert and independent director and that John Zotos is an independent director.

 

Roman Gordon is a brother of Mr. Igor Gorodnitsky

 

ITEM 14.  Principal Accounting Fees and Services

 

Independent Registered Public Accounting Firm’s Fee Summary

 

The following table provides information regarding the fees billed to us by Weinberg & Company, P.A. for the years ended June 30, 2017 and 2016. All fees described below were approved by the Board:

   

		June 30, 2017				June 30, 2016
Audit Fees and Expenses (1)		$	68,140			$	76,730
Audit Related Fees (2)
All Other Fees		$	19,409			$	8,440

 

(1)	Audit fees and expenses were for professional services rendered for the audit and reviews of the consolidated financial statements of the Company, professional services rendered for issuance of consents and assistance with review of documents filed with the SEC.
(2)	The audit related fees were for professional services rendered for additional filing for registration statements and forms with the SEC.

 

Pre-Approval Policies and Procedures

 

Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

 

Prior to the engagement of the independent registered public accounting firm for the next year’s audit, management will submit a list of services and related fees expected to be rendered during that year for audit services, audit-related services, tax services and other fees to the Audit Committee for approval.

 

 

PART IV

 

ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

(a) The following documents are filed as part of this annual report on Form 10-K:

 

1.   Financial Statements

 

The financial statements are filed as part of this report under Item 8 “Financial Statements and Supplementary Data”.

 

2.   Financial Statement Schedules

 

All other schedules are omitted because they are not applicable or the required information is presented in the financial statements and notes thereto.

 

3.   Exhibits

 

The exhibits required by Item 601 of Regulation S-K are included in Item 15(b) below.

 

(b) - Exhibits. 

 

Exhibit

Filed

Incorporated by Reference

Number

Exhibit Description

Herewith

Form

Period Ended

Exhibit

Filing Date

3(i)(a)

Articles of Incorporation - original name of Bioenergy, Inc.

SB-2

N/A

3.1

October 19, 2006

3(i)(b)

Articles of Incorporation - Amended and Restated

10-Q

December 31, 2008

3-1

February 17, 2009

3(i)(c)

Articles of Incorporation - Amended and Restated

10-Q

June 30, 2009

3-1

May 14, 2009

3(i)(d)

Articles of Incorporation - Amended; increase in authorized shares

8-K

N/A

N/A

October 29, 2009

3(i)(e)

Articles of Incorporation - Certificate of Amendment; forward split

10-Q

September 30, 2009

3-1

November 16, 2009

10.1

Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.

8-K

June 30, 2009

10.1

May 18, 2010

10.2

Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.

8-K

June 30, 2009

10.2

May 18, 2010

10.3

Assignment of Patent Assignment Agreement between the Company and Roman Gordon

8-K

June 30, 2009

10.3

May 18, 2010

10.4

Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky

8-K

June 30, 2009

10.4

May 18, 2010

10.5

Employment Agreement between the Company and Roman Gordon date March 17, 2008

10-K/A

June 30, 2009

10.3

October 20, 2011

10.6

Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008

10-K/A

June 30, 2009

10.4

October 20, 2011

10.7

Employment Agreement with R.L. Hartshorn dated Sept. 22, 2009

10-Q

December 31, 2011

10.70

February 10, 2012

10.8

Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008

10-Q

December 31, 2010

10.3

February 11, 2011

10.9

Board of Director Agreement - James Fuller

10-Q

December 31, 2011

10.12

October 20, 2011

10.10

Technology and License Agreement with Desmet Ballestra dated  May 14, 2012

10-K

June 30, 2012

10.10

October 12, 2012

10.11

Convertible Note Payable - Prolific Group LLC - $25,000

10-Q

December 31, 2011

10.40

February 10, 2012

10.12

Convertible Note Payable - Tripod Group LLC - $30,000

10-Q

December 31, 2011

10.41

February 10, 2012

14.1

Code of Business Conduct and Ethics*

10-K

June 30, 2011

14.1

September 28, 2011

31.1

Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002

X

31.2

Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002

X

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

 

 

 

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

99.1

Loan Agreement - Desmet Ballestra - Oct. 26, 2010

10-Q

September 30, 2010

99.1

November 12, 2010

101.INS

XBRL Instance Document

X

101.SCH

XBRL Taxonomy Extension Schema

X

101.CAL

XBRL Taxonomy Extension Calculation Linkbase

X

101.DEF

XBRL Taxonomy Extension Definition Linkbase

X

101.LAB

XBRL Taxonomy Extension Label Linkbase

X

101.PRE

XBRL Taxonomy Extension Presentation Linkbase

X

*

In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our “Code of Business Conduct and Ethics”. A copy may be requested by sending an email to info@cavitationtechnologies.com.

 

(c) - Financial Statement Schedules

 

See Item (a) 2 above.

 

ITEM 16. SUMMARY. FORM 10-K SUMMARY

 

Not applicable

 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN THE CAPACITIES AND ON THE DATES INDICATED

 

SIGNATURE		TITLE		DATE
/s/ Igor Gorodnitsky		President; Member of Board of Directors		November 3, 2017
Igor Gorodnitsky		(Principal Executive Officer)
/s/ N. Voloshin		Chief Financial Officer		November 3, 2017
N. Voloshin		(Principal Financial Officer)
/s/ James Fuller		Audit Committee Chairman,		November 3, 2017
James Fuller		Independent Financial Expert